SG10201609412QA - Treatment of amd using aav sflt-1 - Google Patents
Treatment of amd using aav sflt-1Info
- Publication number
- SG10201609412QA SG10201609412QA SG10201609412QA SG10201609412QA SG10201609412QA SG 10201609412Q A SG10201609412Q A SG 10201609412QA SG 10201609412Q A SG10201609412Q A SG 10201609412QA SG 10201609412Q A SG10201609412Q A SG 10201609412QA SG 10201609412Q A SG10201609412Q A SG 10201609412QA
- Authority
- SG
- Singapore
- Prior art keywords
- amd
- treatment
- sflt
- aav
- aav sflt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/02—Subjective types, i.e. testing apparatus requiring the active assistance of the patient
- A61B3/028—Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing visual acuity; for determination of refraction, e.g. phoropters
- A61B3/032—Devices for presenting test symbols or characters, e.g. test chart projectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647461P | 2012-05-15 | 2012-05-15 | |
US201261670535P | 2012-07-11 | 2012-07-11 | |
US201261678555P | 2012-08-01 | 2012-08-01 | |
US201261691660P | 2012-08-21 | 2012-08-21 | |
US201361775440P | 2013-03-08 | 2013-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201609412QA true SG10201609412QA (en) | 2017-01-27 |
Family
ID=49584435
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407548UA SG11201407548UA (en) | 2012-05-15 | 2013-05-07 | Treatment of amd using aav sflt-1 |
SG10201609412QA SG10201609412QA (en) | 2012-05-15 | 2013-05-07 | Treatment of amd using aav sflt-1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407548UA SG11201407548UA (en) | 2012-05-15 | 2013-05-07 | Treatment of amd using aav sflt-1 |
Country Status (27)
Country | Link |
---|---|
US (7) | US20130323302A1 (es) |
EP (2) | EP2849802B1 (es) |
JP (5) | JP6466322B2 (es) |
KR (3) | KR102218067B1 (es) |
CN (2) | CN104994882A (es) |
AU (3) | AU2013263159B2 (es) |
BR (1) | BR112014028633A8 (es) |
CA (1) | CA2873628C (es) |
CY (1) | CY1124495T1 (es) |
DK (1) | DK3501549T3 (es) |
ES (2) | ES2967616T3 (es) |
HK (1) | HK1207568A1 (es) |
HR (1) | HRP20211453T1 (es) |
HU (1) | HUE056327T2 (es) |
IL (2) | IL235679B (es) |
LT (1) | LT3501549T (es) |
MX (2) | MX362452B (es) |
NZ (2) | NZ727516A (es) |
PL (1) | PL3501549T3 (es) |
PT (1) | PT3501549T (es) |
RS (1) | RS62359B1 (es) |
RU (1) | RU2014150340A (es) |
SG (2) | SG11201407548UA (es) |
SI (1) | SI3501549T1 (es) |
TW (3) | TWI775096B (es) |
WO (1) | WO2013173129A2 (es) |
ZA (1) | ZA201409025B (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9730790B2 (en) | 2009-09-29 | 2017-08-15 | Edwards Lifesciences Cardiaq Llc | Replacement valve and method |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
PL3254703T3 (pl) | 2011-04-22 | 2020-10-05 | The Regents Of The University Of California | Wiriony wirusa towarzyszącego adenowirusom z różnymi kapsydami i sposoby ich zastosowania |
TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
CA2907799A1 (en) | 2013-05-31 | 2014-12-04 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
KR101591823B1 (ko) * | 2013-12-27 | 2016-02-04 | 재단법인 목암생명공학연구소 | 증가된 유전자 발현능을 갖는 발현벡터 |
EP3102246B1 (en) * | 2014-02-06 | 2020-03-25 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
CA2942776C (en) * | 2014-03-17 | 2023-01-24 | Adverum Biotechnologies, Inc. | Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter |
ES2774552T3 (es) * | 2014-03-24 | 2020-07-21 | Translate Bio Inc | Terapia de ARNm para el tratamiento de enfermedades oculares |
WO2015153889A2 (en) * | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
HUE054768T2 (hu) | 2014-05-02 | 2021-09-28 | Genzyme Corp | AAV vektorok retina és CNS génterápiára |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
GB201502137D0 (en) | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
EP3748007A1 (en) * | 2015-03-06 | 2020-12-09 | Massachusetts Eye & Ear Infirmary | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
AU2016235163B2 (en) | 2015-03-24 | 2022-03-24 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
EP3294890A4 (en) * | 2015-05-08 | 2018-10-03 | Children's Medical Research Institute | Promoters for expression of heterologous genes |
EP3294309A4 (en) * | 2015-05-14 | 2019-01-16 | St. Jude Children's Research Hospital, Inc. | NUCLEIC ACID MOLECULES WITH SPACERS AND METHOD FOR USE THEREOF |
US10016514B2 (en) | 2015-05-15 | 2018-07-10 | New Hope Research Foundation | Polynucleotides, vectors and methods for insertion and expression of transgenes |
AU2016338565B2 (en) * | 2015-10-14 | 2021-11-18 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
BR112018011059A2 (pt) | 2015-12-03 | 2018-11-21 | Friedrich Miescher Institute For Biomedical Research | synp161, um promotor para a expressão específica de genes em fotoreceptores de haste |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
SG10202008378UA (en) * | 2016-04-15 | 2020-10-29 | Regenxbio Inc | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
EP3452103A1 (en) * | 2016-04-15 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
RU2018142273A (ru) * | 2016-05-03 | 2020-06-03 | Чжо-хуа Пань | Способ улучшения опосредованной вирусами доставки генов в глаз с использованием ингибиторов протеасом |
RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
AU2017286680B2 (en) * | 2016-06-16 | 2023-01-19 | Adverum Biotechnologies, Inc. | Compositions and methods for reducing ocular neovascularization |
RS61311B1 (sr) | 2016-06-16 | 2021-02-26 | Adverum Biotechnologies Inc | Lečenje amd korišćenjem varijante aav2 sa afliberceptom |
MX2019001276A (es) | 2016-07-29 | 2019-06-13 | Univ California | Viriones de virus adenoasociados con cápside variante y métodos para su uso. |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
CN107058315B (zh) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
EP3595687A1 (en) * | 2017-03-16 | 2020-01-22 | Lineage Cell Therapeutics, Inc. | Methods for measuring therapeutic effects of retinal disease therapies |
MX2019011040A (es) * | 2017-03-17 | 2020-01-20 | Adverum Biotechnologies Inc | Composiciones y metodos para potenciar la expresion genica. |
SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
EP3676373A4 (en) | 2017-08-28 | 2021-06-09 | The Regents of The University of California | CAPSID VARIANTS OF ADENO-ASSOCIATED VIRUSES AND METHOD OF USING THEREOF |
AU2018342094A1 (en) * | 2017-09-27 | 2020-04-02 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
JP2021502060A (ja) | 2017-10-16 | 2021-01-28 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)の治療 |
KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
US10610606B2 (en) * | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
EP3762500A1 (en) | 2018-03-06 | 2021-01-13 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
EP3790394A4 (en) * | 2018-05-08 | 2022-07-27 | Rutgers, the State University of New Jersey | POLYMERIZING PROTEINS AAV-COMPATIBLE LAMININ LINKER |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
CN112567035A (zh) | 2018-07-02 | 2021-03-26 | 沃雅戈治疗公司 | 肌萎缩侧索硬化症及脊髓相关病症的治疗 |
US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
US20210348242A1 (en) | 2018-10-04 | 2021-11-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
US20220016213A1 (en) | 2018-11-28 | 2022-01-20 | Genascence Corporation | Methods and Compositions for Treating Osteoarthritis |
WO2020136384A1 (en) * | 2018-12-28 | 2020-07-02 | Constable Ian Jeffery | Methods of retinal administration |
AU2020208467A1 (en) | 2019-01-18 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing AAV particles |
JP2022522776A (ja) | 2019-03-04 | 2022-04-20 | アドヴェラム バイオテクノロジーズ, インコーポレイテッド | 対側眼へのaav遺伝子治療の逐次的硝子体内投与 |
TW202106699A (zh) | 2019-04-26 | 2021-02-16 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
TW202106879A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法 |
EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20220364114A1 (en) | 2019-08-26 | 2022-11-17 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
KR20220083712A (ko) * | 2019-09-20 | 2022-06-20 | 메이라지티엑스 테라퓨틱스, 인크. | 주입 시스템 및 사용 방법 |
CN112552410A (zh) * | 2019-09-26 | 2021-03-26 | 三生国健药业(上海)股份有限公司 | 一种抗体融合蛋白及其制法和在抗肿瘤中的应用 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
WO2021112597A1 (ko) * | 2019-12-04 | 2021-06-10 | 주식회사 씨드모젠 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 당뇨망막병증 치료용 조성물 |
EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20220267795A1 (en) * | 2021-02-24 | 2022-08-25 | Kinase Pharma Inc. | Compositions and methods for regulating production of an angiogensis inhibitor |
WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
KR20240014477A (ko) | 2021-05-28 | 2024-02-01 | 상하이 레제네리드 테라피즈 컴퍼니 리미티드 | 변이체 캡시드를 갖는 재조합 아데노-연관 바이러스 및 이의 응용 |
WO2023206134A1 (en) * | 2022-04-27 | 2023-11-02 | Beijing Sightnovo Medical Technology Co., Ltd | Compositions and methods for eye diseases |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4874237A (en) | 1987-05-07 | 1989-10-17 | Lions Eye Inst. Of Western Australia | Electroretinogram apparatus |
AU631159B2 (en) | 1988-11-14 | 1992-11-19 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Parvovirus capsids |
FR2643252B1 (fr) | 1989-02-21 | 1991-06-07 | Technomed Int Sa | Appareil de destruction selective de cellules incluant les tissus mous et les os a l'interieur du corps d'un etre vivant par implosion de bulles de gaz |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6287815B1 (en) | 1989-09-14 | 2001-09-11 | Rijksuniversiteit Te Leiden | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
US5383917A (en) | 1991-07-05 | 1995-01-24 | Jawahar M. Desai | Device and method for multi-phase radio-frequency ablation |
ATE281469T1 (de) * | 1993-03-25 | 2004-11-15 | Merck & Co Inc | Inhibitor des wachstumsfaktors für gefäss- endothelzellen |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
FR2718150B1 (fr) | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
US20020168342A1 (en) | 1994-11-03 | 2002-11-14 | Cell Genesys, Inc. | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5641749A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US6054485A (en) * | 1996-08-20 | 2000-04-25 | Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
JP2001501471A (ja) | 1996-09-24 | 2001-02-06 | メルク エンド カンパニー インコーポレーテッド | 血管新生の阻害のための遺伝子治療 |
FR2756297B1 (fr) | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | Procede de production de virus recombinants |
US6153436A (en) | 1997-01-10 | 2000-11-28 | The Board Of Trustees Of The University Of Arkansas | Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions |
AU728220B2 (en) | 1997-04-14 | 2001-01-04 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
AU7383298A (en) | 1997-05-13 | 1998-12-08 | Regents Of The University Of California, The | Novel antiangiogenic peptide agents and their therapeutic and diagnostic use |
US6458157B1 (en) * | 1997-08-04 | 2002-10-01 | Suaning Gregg Joergen | Retinal stimulator |
CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
JPH11100327A (ja) | 1997-09-26 | 1999-04-13 | Toray Ind Inc | 網膜変性症治療剤 |
EP1019515A1 (en) | 1997-10-01 | 2000-07-19 | G.D. SEARLE & CO. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
WO1999036511A2 (en) | 1998-01-16 | 1999-07-22 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
CA2322380C (en) | 1998-03-12 | 2008-10-14 | Genentech, Inc. | Method of preventing the death of retinal neurons and treating ocular diseases |
US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
JP2002528056A (ja) * | 1998-08-28 | 2002-09-03 | デューク・ユニバーシティー | IVa2、100K及び/又は末端前タンパク質配列における欠失型アデノウイルス |
AU775245B2 (en) | 1998-09-17 | 2004-07-22 | Catholic University Nijmegen | Methods for treatment of degenerative retinal diseases |
US20040234505A1 (en) | 1998-09-23 | 2004-11-25 | Stuart Naylor | Polynucleotide constructs and uses thereof |
US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
WO2000054813A2 (en) * | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
AU2619301A (en) | 1999-10-25 | 2001-06-06 | Therus Corporation | Use of focused ultrasound for vascular sealing |
WO2001078586A1 (en) | 2000-04-17 | 2001-10-25 | Stuart Graham | Method and apparatus for objective electrophysiological assessment of visual function |
US6329181B1 (en) | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
AU2002236988A1 (en) * | 2001-02-06 | 2002-08-19 | Novartis Ag | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
WO2002076355A2 (de) | 2001-03-27 | 2002-10-03 | Wavelight Laser Technologie Ag | Verfahren und vorrichtung zur bearbeitung und diagnose von augengewebe |
EP1381276A4 (en) | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION |
JP2002363107A (ja) | 2001-06-04 | 2002-12-18 | Noriyuki Azuma | 色覚不全動物の色覚復元方法 |
EP1412493B1 (en) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
WO2003080648A2 (en) | 2002-03-20 | 2003-10-02 | University Of Florida Research Foundation, Inc. | Raav vector compositions and methods for the treatment of choroidal neovascularization |
US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
US8304233B2 (en) | 2002-06-04 | 2012-11-06 | Poetic Genetics, Llc | Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same |
US7220577B2 (en) | 2002-08-28 | 2007-05-22 | University Of Florida Research Foundation, Inc. | Modified AAV |
GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
WO2004079332A2 (en) * | 2003-03-04 | 2004-09-16 | National Institute Of Advanced Industrial Science And Technology | Composition and method for increasing efficiency of introduction of target substance into cell |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US20060166363A1 (en) | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
EP1802334B1 (en) * | 2004-10-21 | 2012-08-29 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
ES2384391T3 (es) | 2004-11-08 | 2012-07-04 | Chromagenics B.V. | Selección de células hospedantes que expresan proteína a altos niveles |
US7922670B2 (en) | 2005-02-24 | 2011-04-12 | Warren Jones | System and method for quantifying and mapping visual salience |
ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
AU2006304997B2 (en) | 2005-10-20 | 2012-03-01 | Uniqure Ip B.V. | Improved AAV vectors produced in insect cells |
WO2007084773A2 (en) | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
US20070190028A1 (en) | 2006-02-13 | 2007-08-16 | Jihong Qu | Method and apparatus for heat or electromagnetic control of gene expression |
US7384145B2 (en) | 2006-02-16 | 2008-06-10 | The Board Of Trustees Of The University Of Illinois | Mapping retinal function using corneal electrode array |
US8118752B2 (en) | 2006-02-16 | 2012-02-21 | The Board Of Trustees Of The University Of Illinois | Apparatus and methods for mapping retinal function |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN101437543A (zh) * | 2006-05-04 | 2009-05-20 | 佛维雅制药股份有限公司 | 用于治疗新生血管病的包含vegf抑制剂和丝氨酸蛋白酶的组合 |
WO2007146953A2 (en) * | 2006-06-12 | 2007-12-21 | Exegenics, Inc., D/B/A Opko Health, Inc. | Compositions and methods for sirna inhibition of angiogenesis |
GB0612096D0 (en) | 2006-06-19 | 2006-07-26 | Greater Glasgow Nhs Board | Functional imaging of the retina |
ES2785223T3 (es) | 2006-06-21 | 2020-10-06 | Uniqure Ip Bv | Células de insecto para la producción de vectores de AAV |
US20100008170A1 (en) | 2006-06-27 | 2010-01-14 | Shinya Sato | Semiconductor tester and testing method of semiconductor memory |
WO2008024998A2 (en) | 2006-08-24 | 2008-02-28 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
AU2008215181A1 (en) | 2007-02-16 | 2008-08-21 | Objectivision Limited | Stimulus method for multifocal visual evoked potential |
EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
US10696983B2 (en) | 2007-05-30 | 2020-06-30 | The Trustees Of The University Of Pennsylvania | Method for transducing cells with primary cilia |
WO2009023805A1 (en) | 2007-08-16 | 2009-02-19 | The Research Foundation Of State University Of New York | Led variable light source |
US8518037B2 (en) | 2007-10-30 | 2013-08-27 | Boston Scientific Scimed, Inc. | Radiofrequency ablation device |
US20110053274A1 (en) * | 2007-11-30 | 2011-03-03 | Scarab Genomics Llc | Lac expression system |
US8642314B2 (en) | 2008-02-19 | 2014-02-04 | Amsterdam Molecular Therapeutics (Amt) B.V. | Optimization of expression of parvoviral rep and cap proteins in insect cells |
CN101951925A (zh) | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
ITFI20080081A1 (it) | 2008-04-18 | 2009-10-19 | Strumenti Oftalmici C S O S R | Procedimento e sistema per la registrazione di risposte elettrofunzionali erg, perg e vep multifocali in tempo reale |
WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
ES2330826B1 (es) | 2008-06-04 | 2010-07-26 | Proyecto De Biomedicina Cima, S.L. | Sistema para empaquetamiento de adenovirus de alta capacidad. |
DK2403867T3 (da) | 2009-03-04 | 2019-08-12 | Deutsches Krebsforsch | Assembly activating protein (aap) og dets anvendelse til fremstilling af parvoviruspartikler hovedsageligt bestående af vp3 |
US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
TWI466158B (zh) | 2009-07-03 | 2014-12-21 | Univ Lunghwa Sci & Technology | 電漿測量裝置、電漿系統及測量電漿特性之方法 |
EP2287323A1 (en) * | 2009-07-31 | 2011-02-23 | Association Institut de Myologie | Widespread gene delivery to the retina using systemic administration of AAV vectors |
EP2292781A1 (en) | 2009-08-17 | 2011-03-09 | Genethon | Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions |
WO2011034947A2 (en) | 2009-09-15 | 2011-03-24 | University Of Washington | Reagents and methods for modulating cone photoreceptor activity |
WO2011088081A1 (en) | 2010-01-12 | 2011-07-21 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
US9228174B2 (en) | 2010-03-11 | 2016-01-05 | Uniqure Ip B.V. | Mutated rep encoding sequences for use in AAV production |
CA2793633A1 (en) * | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
US9102718B2 (en) * | 2010-04-30 | 2015-08-11 | Lpath, Inc. | Anti-S1P antibody treatment of patients with ocular disease |
CN201704771U (zh) | 2010-04-30 | 2011-01-12 | 陈福环 | 无水箱节水型抽水马桶 |
WO2011140450A1 (en) | 2010-05-07 | 2011-11-10 | Medicinelodge, Inc Dba Imds Co-Innovation | Surgical rasp with radiofrequency ablation |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
EP2640743B1 (en) | 2010-11-16 | 2016-10-05 | Excelimmune, Inc. | Methods for producing recombinant proteins |
EP3591055A1 (en) | 2011-01-07 | 2020-01-08 | Applied Genetic Technologies Corporation | Promoters derived from the 5' nontranslated region (5'-ntr) of the human cyclic nucleotide gated beta 3 (cngb3) gene, expression cassettes and vectors comprising said promoters, for use treating achromatopsia and other diseases |
PL3254703T3 (pl) | 2011-04-22 | 2020-10-05 | The Regents Of The University Of California | Wiriony wirusa towarzyszącego adenowirusom z różnymi kapsydami i sposoby ich zastosowania |
WO2013063601A1 (en) | 2011-10-28 | 2013-05-02 | University Of Florida Research Foundation, Inc. | Chimeric promoter for cone photoreceptor targeted gene therapy |
TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
US20150111275A1 (en) | 2012-06-11 | 2015-04-23 | Daniel V. Palanker | Optical regulation of gene expression in the retina |
EP3013946B8 (en) | 2013-06-28 | 2019-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for expressing a polynucleotide of interest in the retina of a subject |
US20150025939A1 (en) | 2013-07-18 | 2015-01-22 | Somnath Chatterjee | Company Centric Social Media Platfonn for Content Sharing aud Tracking |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
EP3049527A4 (en) | 2013-09-26 | 2017-08-16 | University of Florida Research Foundation, Inc. | Synthetic combinatorial aav capsid library for targeted gene therapy |
EP3113787B1 (en) | 2014-03-04 | 2019-12-04 | University of Florida Research Foundation, Inc. | Improved raav vectors and methods for transduction of photoreceptors and rpe cells |
CA2942776C (en) | 2014-03-17 | 2023-01-24 | Adverum Biotechnologies, Inc. | Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter |
KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
-
2013
- 2013-05-06 TW TW109119818A patent/TWI775096B/zh active
- 2013-05-06 TW TW102116146A patent/TWI702955B/zh active
- 2013-05-06 TW TW107100972A patent/TWI698240B/zh active
- 2013-05-07 ES ES13791695T patent/ES2967616T3/es active Active
- 2013-05-07 CN CN201380037577.3A patent/CN104994882A/zh active Pending
- 2013-05-07 WO PCT/US2013/040011 patent/WO2013173129A2/en active Application Filing
- 2013-05-07 ES ES18198081T patent/ES2890813T3/es active Active
- 2013-05-07 JP JP2015512688A patent/JP6466322B2/ja active Active
- 2013-05-07 AU AU2013263159A patent/AU2013263159B2/en active Active
- 2013-05-07 HR HRP20211453TT patent/HRP20211453T1/hr unknown
- 2013-05-07 SI SI201331931T patent/SI3501549T1/sl unknown
- 2013-05-07 NZ NZ727516A patent/NZ727516A/en unknown
- 2013-05-07 US US13/889,275 patent/US20130323302A1/en not_active Abandoned
- 2013-05-07 RS RS20211170A patent/RS62359B1/sr unknown
- 2013-05-07 CN CN202210624338.9A patent/CN115337407A/zh active Pending
- 2013-05-07 SG SG11201407548UA patent/SG11201407548UA/en unknown
- 2013-05-07 DK DK18198081.4T patent/DK3501549T3/da active
- 2013-05-07 MX MX2014013933A patent/MX362452B/es active IP Right Grant
- 2013-05-07 CA CA2873628A patent/CA2873628C/en active Active
- 2013-05-07 KR KR1020207025521A patent/KR102218067B1/ko active IP Right Grant
- 2013-05-07 SG SG10201609412QA patent/SG10201609412QA/en unknown
- 2013-05-07 BR BR112014028633A patent/BR112014028633A8/pt not_active Application Discontinuation
- 2013-05-07 HU HUE18198081A patent/HUE056327T2/hu unknown
- 2013-05-07 PL PL18198081T patent/PL3501549T3/pl unknown
- 2013-05-07 KR KR1020217004455A patent/KR20210021111A/ko not_active Application Discontinuation
- 2013-05-07 LT LTEP18198081.4T patent/LT3501549T/lt unknown
- 2013-05-07 KR KR1020147035050A patent/KR102154225B1/ko active IP Right Grant
- 2013-05-07 RU RU2014150340A patent/RU2014150340A/ru not_active Application Discontinuation
- 2013-05-07 EP EP13791695.3A patent/EP2849802B1/en active Active
- 2013-05-07 PT PT181980814T patent/PT3501549T/pt unknown
- 2013-05-07 EP EP18198081.4A patent/EP3501549B1/en active Active
- 2013-05-07 NZ NZ702637A patent/NZ702637A/en unknown
-
2014
- 2014-05-19 US US14/281,783 patent/US20140371438A1/en not_active Abandoned
- 2014-05-19 US US14/281,765 patent/US20140341977A1/en not_active Abandoned
- 2014-05-19 US US14/281,749 patent/US9943573B2/en active Active
- 2014-11-13 IL IL235679A patent/IL235679B/en active IP Right Grant
- 2014-11-14 MX MX2019000586A patent/MX2019000586A/es unknown
- 2014-12-09 ZA ZA2014/09025A patent/ZA201409025B/en unknown
-
2015
- 2015-08-25 HK HK15108214.6A patent/HK1207568A1/xx unknown
-
2017
- 2017-10-30 JP JP2017209139A patent/JP6667486B2/ja active Active
- 2017-12-21 US US15/851,650 patent/US10004788B2/en active Active
-
2018
- 2018-04-24 US US15/961,654 patent/US20180311319A1/en not_active Abandoned
- 2018-07-31 AU AU2018211212A patent/AU2018211212B2/en active Active
-
2019
- 2019-02-20 JP JP2019028448A patent/JP2019071908A/ja not_active Withdrawn
-
2020
- 2020-12-18 JP JP2020209916A patent/JP2021045170A/ja not_active Withdrawn
-
2021
- 2021-01-15 AU AU2021200253A patent/AU2021200253A1/en not_active Abandoned
- 2021-03-25 IL IL281833A patent/IL281833A/en unknown
- 2021-05-24 US US17/328,705 patent/US20220111015A1/en active Pending
- 2021-09-15 CY CY20211100812T patent/CY1124495T1/el unknown
-
2022
- 2022-05-09 JP JP2022077005A patent/JP2022106929A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281833A (en) | Treatment of AMD with AAV SFLT-1 | |
HRP20180939T1 (hr) | Kombinirana terapija za liječenje multiple skleroze | |
EP2819703A4 (en) | TREATMENT OF PAIN | |
EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
GB201506561D0 (en) | Treatment of amblyopia | |
GB2502133B (en) | Treatment or therapeutic apparatus | |
ZA201308176B (en) | Therapeutic treatment | |
FI3473276T3 (fi) | Tekniikoita paiseiden hoitoon | |
HK1210421A1 (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3- | |
GB201221118D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201206325D0 (en) | Methods of treatment | |
GB201206324D0 (en) | Methods of treatment | |
GB201206330D0 (en) | Methods of treatment | |
GB201206326D0 (en) | Methods of treatment | |
GB201208505D0 (en) | Treatment of skin condition | |
GB201214456D0 (en) | Therapeutic treatments | |
GB201214454D0 (en) | Therapeutic treatments |